알레르기 면역요법 시장 규모는 2023년에 20억 8,000만 달러로 평가되었고, 2031년까지 38억 7,000만 달러의 성장이 예측되고, 예측 기간 중의 CAGR은 8.10%를 나타낼 것으로 예상됩니다. 알레르기성 비염, 천식, 음식 알레르기 등의 알레르기 질병의 빈도 증가로 확대되고 있습니다. 효과적이고 장기적인 치료법을 요구하는 사람이 늘어남에 따라, 표준 약물보다 면역요법을 선호하는 경향이 명확해지고 있습니다. 약물이나 코르티코 스테로이드 약물을 항상 사용하지 않고 증상을 완화하려는 사람들에게 특히 적합합니다.
또한, 알레르겐 특이적 면역요법 제품과 설하정이나 주사 등의 투여방법의 진보로 환자의 접근과 어드히어런스가 향상되고 있습니다. 확대의 원동력이 되고 있습니다. 맞춤형 의료가 중시되는 가운데, 알레르기 면역요법 산업은 향후 수년간 크게 성장할 것으로 예상됩니다.
알레르기 면역요법 시장 정의/개요
알레르기 면역 요법은 알레르겐에 대한 감수성을 감소시키고 알레르기 증상을 장기적으로 완화시키는 것을 목적으로 한 치료법입니다. 특정 알레르겐을 피하 주사 겐 면역요법) 또는 설하정/점적으로 서서히 증량해 갑니다.
특정 알레르겐에 대한 면역계의 감수성을 서서히 저하시킴으로써 알레르기 질환을 치료합니다. 시간이 지남에 알레르기 반응의 중증도를 낮추고 치료가 끝난 후에도 장기간 증상을 완화시킬 수 있습니다. 삶의 질을 높이고 약물 사용량을 줄입니다.
알레르기 면역 요법의 미래는 유전자와 바이오 마커의 데이터를 이용하여 특정 환자에게 약물을 적응시키는 맞춤형 치료 기술이 중심이 될 것으로 보입니다. 환자의 컴플라이언스와 편안함을 향상시킬 것으로 기대되고 있습니다.
건강 관리 전문가와 환자 사이의 의식이 높아짐에 따라 알레르기 면역 요법 시장의 성장이 가속화되고 있습니다. 장점이 있음을 인식하고 실행 가능한 알레르기 치료 옵션으로 역요법을 추진하게 되어 있습니다. 면역요법의 효능과 안전성에 관한 교육의 향상에 추진된 이러한 임상실천의 변화는 피하면역요법(SCIT)이나 설하면역요법(SLIT) 같은 치료법의 수용 확대로 이어져 시장의 성장에 기여하고 있습니다.
환자의 관점에서 알레르기 면역 요법이 일시적인 증상 완화뿐만 아니라 장기적인 편안함을 제공하는 능력에 대한 이해가 깊어지고 이러한 요법에 대한 수요가 증가하고 있습니다. 환자는 자신의 선택을 더 잘 이해하고 개인화된 장기적인 알레르기 치료를 선택할 가능성이 높아지고 있습니다. 이러한 수요 증가와 헬스케어 전문가의 추천이 함께, 면역요법의 채용이 진행되고 시장 전체가 확대되고 있습니다.
높은 치료 비용은 알레르기 면역 요법 시장에서 환자의 치료에 대한 접근을 제한하는 큰 장벽이되었습니다. 알레르기 면역요법, 특히 피하면역요법(SCIT)은 수년에 걸쳐 여러 번의 치료가 필요하며 환자에게는 고가의 치료비가 됩니다. 많은 지역에서는 이러한 치료에 대한 보험 적용이 제한적이거나 적용되지 않을 수 있으며 환자는 현금으로 지불해야합니다. 이 치료법은 만성 알레르기 문제를 장기적으로 완화시키는 것이지만, 많은 사람들은 그 비용의 높이에 두 발을 밟고 있습니다.
게다가 면역요법에는 고액의 초기 비용과 경상비용이 걸리기 때문에 특히 저소득 지역이나 헬스케어 자원이 불충분한 나라에서는 그 이용이 제한되고 있습니다. 대규모 면역요법 프로그램을 위해 자원을 나누는 것은 재정에 여유가 없는 헬스케어 시스템에 있어서는 현실적이지 않을 수 있으며, 시장 확대는 더욱 제한됩니다. 그 결과, 알레르기의 이환율이 증가하고, 면역요법의 효능이 확립되었음에도 불구하고, 이러한 치료법의 보급에는 비용이 큰 장벽이 되고 있습니다.
Allergy Immunotherapy Market size was valued at USD 2.08 Billion in 2023 and is projected to grow USD 3.87 Billion by 2031, exhibiting a CAGR of 8.10% during the forecast period. The Allergy Immunotherapy Market is expanding due to the increasing frequency of allergic illnesses such as allergic rhinitis, asthma, and food allergies. As more people seek effective, long-term treatment alternatives, the preference for immunotherapy over standard drugs is becoming clear. This is especially true for people who want to relieve their symptoms without having to use antihistamines or corticosteroids all the time.
Furthermore, advances in allergen-specific immunotherapy products and administration modalities such as sublingual tablets and injections, are improving patient access and adherence. Increasing awareness of immunotherapy's benefits combined with recommendations from healthcare experts is driving market expansion. With an emphasis on personalized medication, the allergy immunotherapy industry is expected to grow significantly in the coming years.
Allergy Immunotherapy Market: Definition/ Overview
Allergy immunotherapy is a treatment that aims to lower sensitivity to allergens resulting in long-term relief from allergy symptoms. It entails gradually administering increasing doses of certain allergens, either via subcutaneous injections (allergen immunotherapy) or sublingual tablets/drops. This mechanism helps the immune system develop tolerance to allergens reducing the severity of allergic reactions.
It is used to treat allergy diseases by progressively reducing the immune system's sensitivity to specific allergens. It entails the introduction of allergens in controlled dosages by injections (subcutaneous immunotherapy) or sublingual pills. This approach reduces the severity of allergic reactions over time and can provide long-term relief, even after therapy is completed. Allergy immunotherapy is beneficial for illnesses such as allergic rhinitis, asthma, and specific food allergies enhancing patients' quality of life and lowering drug use.
The future of allergy immunotherapy will center on personalized treatment techniques that use genetic and biomarker data to adapt medicines to specific patients. Innovative drug delivery systems, such as microneedles and wearable devices are expected to improve patient compliance and comfort. Furthermore, studies on new allergen sources and combination medicines will expand therapy choices.
Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.
Rising awareness among healthcare professionals and patients has accelerated the growth of the Allergy Immunotherapy Market. As more healthcare practitioners recognize the long-term benefits of immunotherapy over traditional allergy medications, they are more likely to promote it as a viable allergy management option. This shift in clinical practice, fuelled by improved education on the efficacy and safety of immunotherapy has resulted in increased acceptance of therapies such as Subcutaneous Immunotherapy (SCIT) and Sublingual Immunotherapy (SLIT), hence contributing to market growth.
From the patient's perspective, a rising understanding of allergy immunotherapy's ability to provide long-term comfort, rather than just temporary symptom relief has resulted in increased demand for these therapies. As patients become more aware of their alternatives, they are more likely to choose personalized, long-term allergy treatments. This rising demand combined with professional endorsements from healthcare practitioners has pushed the adoption of immunotherapy propelling total market expansion.
The high cost of treatment is a significant barrier in the Allergy Immunotherapy Market limiting patient access to care. Allergy immunotherapy, particularly Subcutaneous Immunotherapy (SCIT) needs several sessions over several years which can be costly for patients. In many areas, insurance coverage for such therapies may be limited or absent requiring patients to pay out of cash. Even though the therapy provides long-term relief for chronic allergy problems, many people are put off by the cost.
Furthermore, the high initial and recurring costs associated with immunotherapy limit its accessibility, particularly in low-income regions or nations with inadequate healthcare resources. Allocating resources for extensive immunotherapy programs may be impractical for healthcare systems with limited finances, further restricting market expansion. As a result, despite the increasing incidence of allergies and the established efficacy of immunotherapy, cost remains a significant barrier to the wider use of these treatments.
Subcutaneous Immunotherapy (SCIT) dominates the Allergy Immunotherapy Market due to its long-standing efficacy and comprehensive strategy. SCIT includes injecting allergen extracts directly under the skin allowing for controlled exposure and eventual desensitization of the immune system to specific allergens. This approach has been widely researched and shown helpful for a variety of allergens, notably pollen, dust mites, and animal dander making it a popular choice among both patients and healthcare providers looking for long-term relief.
Furthermore, SCIT provides a well-defined treatment regimen with established protocols resulting in predictable dose and response. The inclusion of multiple allergens in SCIT formulations allows for more personalized therapy options for patients which improves compliance and satisfaction. While sublingual immunotherapy (SLIT) is gaining popularity due to its simplicity of administration, SCIT remains dominant due to its proven track record, strong clinical data, and allergists' preference for its comprehensive approach to addressing allergic diseases.
Hospital pharmacies dominate the allergy immunotherapy industry because they have access to a wide choice of specialized drugs and treatment alternatives. These pharmacies are ready to prepare and distribute personalized immunotherapy regimens such as allergy injections and sublingual pills, based on patient needs. The presence of allergists and immunologists in hospital settings promotes teamwork, resulting in better patient care and monitoring throughout the therapy process. This integrated strategy guarantees that patients receive timely and effective medicines which leads to better outcomes.
Furthermore, hospital pharmacies benefit from established partnerships with pharmaceutical producers allowing them to obtain the most recent immunotherapy medicines and updates on treatment methods. As hospitals implement multidisciplinary care models, coordination among chemists, healthcare professionals, and patients improves. This comprehensive strategy not only improves patient adherence to medication but also creates a supportive atmosphere for continued education and follow-up reinforcing hospital pharmacies' role in the Allergy Immunotherapy Market.
North America dominates the Allergy Immunotherapy Market, owing to the increasing prevalence of allergic illnesses like allergic rhinitis and asthma which drives demand for better treatment alternatives. The region benefits from excellent healthcare facilities, extensive research programs, and a thriving pharmaceutical sector. Major corporations are significantly investing in novel medicines such as subcutaneous and sublingual immunotherapy, to meet the rising patient population. Furthermore, as healthcare practitioners and patients become more aware of allergic disorders, acceptance and usage of immunotherapy treatments have increased.
Furthermore, supporting regulatory frameworks and favorable reimbursement policies in the United States promote market expansion. The Food and Drug Administration (FDA) has approved several immunotherapy medicines, increasing their market penetration. North American healthcare systems prioritize personalized medicine and patient-centered approaches which encourages the use of allergy immunotherapy. As a result, the region is well-positioned to sustain its market leadership opening the path for ongoing breakthroughs in treatment techniques.
Asia Pacific is the fastest-growing region in the Allergy Immunotherapy Market owing to rising allergy incidence, increased healthcare awareness, and considerable investment in R&D. Urbanisation and changing lifestyles have contributed to an increase in allergy disorders such as asthma and allergic rhinitis creating a larger demand for effective treatments. As more people become aware of the benefits of immunotherapy, healthcare providers are more likely to recommend it resulting in increased market growth.
Furthermore, supportive government initiatives and partnerships with pharmaceutical companies improve access to allergy treatments and advances. The region's increasing middle class is pushing up healthcare spending allowing for the adoption of modern therapeutic choices. Furthermore, the expansion of healthcare infrastructure and the growing number of allergists and immunologists in countries such as China and India are key drivers of market growth. Overall, the combination of increased allergies and greater healthcare access has positioned Asia Pacific as a market leader in allergy immunotherapy.
The Allergy Immunotherapy Market is a dynamic and competitive space characterized by diverse players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations focus on innovating their product line to serve the vast population in diverse regions.
Some of the prominent players operating in the Allergy Immunotherapy Market include:
ALK-Abello A/S, Stallergenes Greer plc, Allergy Therapeutics plc, Merck & Co., Inc. (known as MSD outside of the United States and Canada), Aimmune Therapeutics, Inc., DBV Technologies SA, HAL Allergy Group, Biomay AG, Circassia Pharmaceuticals plc, Immunomic Therapeutics, Inc., Anergis, ASIT Biotech, and Adamis Pharmaceuticals Corporation.
In January 2024, Inimmune Corporation (Inimmune) and Intrommune Therapeutics, Inc. (Intrommune), two clinical-stage immunotherapeutic companies, announced a collaboration to develop a novel oral mucosal allergy immunotherapy for treating peanut allergy.
In October 2023, ALK reported the successful completion of Itulatek's phase 3 trial for treating allergy rhinoconjunctivitis caused by tree pollen.